# Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

> **NCT00499837** · PHASE2 · COMPLETED · sponsor: **Kamada, Ltd.** · enrollment: 21 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Aerosolized, human, plasma-derived Alpha-1 Antitrypsin

## Key facts

- **NCT ID:** NCT00499837
- **Lead sponsor:** Kamada, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499837, "Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00499837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*